
A Review of Stem Cell–Based Therapies for Parkinson Disease
Researchers discuss the development and potential of stem cell–based therapies in the treatment of Parkinson disease.
In assessing treatment for
Discussing in a
Delving into the use of stem cell–based treatments in PD, the researchers say that several important pathways have emerged as targets for potential therapeutic intervention.
“Conventional therapeutic strategies for relieving the symptomatic stages of PD remain, but with new genetic insights, it may be possible to use preventive neuroprotective treatments for people at risk of developing PD,” they highlight. “In parallel with efforts to prevent and control symptomatic PD, researchers are also investigating stem cells as replacements for diseased neurons or degenerated tissues.”
As they note, dopaminergic (DA) cell transplantation is believed to be the most promising cell replacement therapy. Aligned with this approach, a recent
Other notable stem cell–based treatments include:
- Transplantation of fetal ventral mesencephalon (VM) tissue cells to the brains of patients with PD. Fetal VM tissue cells consisted of distinct neuronal populations, including DA neurons of the
substantia nigra andventral tegmental areas , oculomotor neurons, and reticular neurons. - Transplantation of
mesenchymal stem cells (MSCs), which can be isolated from various sources, including adipose tissue and peripheral blood from adult tissues. MSCs have been proven to be beneficial for treating many diseases, including PD, with clinical trials currently underway using MSCs as a therapeutic agent for the condition.
“Although we are not yet examining a disease-modifying treatment, stem cell transplantation has the potential to be at the forefront of such PD treatments in the future,” conclude the researchers. “The transplantation process and the procedures required for its optimization are still not fully understood, and further research is required to achieve treatment for PD.”
Reference
Liu Z, Cheung H-H. Stem cell-based therapies for Parkinson disease. Int J Mol Sci. Published online October 29, 2020. doi:10.3390/ijms21218060
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.